Archive


Category: Chris Anzalone

  • GSK joins NASH chase, paying $120M up front for rights to Arrowhead RNAi drug

    GlaxoSmithKline sees enough promise in the early clinical data of a novel NASH drug to pay its developer, Arrowhead Pharmaceuticals, $120 million up front for rights to the experimental therapy. The Arrowhead drug uses RNA interference to “silence” an enzyme associated with the progression of the fatty liver disease.